News for Prothena Corporation plc (PRTA)

On May 27, Jefferies downgraded Prothena Corporation plc (NASDAQ:PRTA) to Hold from Buy and slashed the price target to $6 from $32. The considerable price target reduction followed the company’s announcement regarding the discontinuation of its Phase 3 AFFIRM-AL clinical trial for Birtamimab in AL Amyloidosis patients, as it could not meet the primary and […]

U.S. stock futures were higher this morning, with the Dow futures gaining more than 500 points on Tuesday. Shares of PDD Holdings Inc. PDD fell sharply in toda...

Prothena Corporation plc (NASDAQ:PRTA) released data from the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis on Friday. AL (amyloid light-chain) amyloidosis is a systemic disease where abnormal proteins, called amyloid fibrils, accumulate in various organs. It’s the most common type of systemic amyloidosis. The Phase 3 AFFIRM-AL trial enrolled 207 newly diagnosed patients. Birtamimab was given to the active arm every 28 days at a dose level of 24 mg/kg (ma

U.S. stock futures rose on Tuesday after closing lower for the week on Friday. Futures of benchmark indices were trading higher in premarket.

Prothena Corporation plc (NASDAQ:PRTA) today announced the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis did not meet

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a...

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dys

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dys

Prothena Corporation is advancing Birtamimab for AL amyloidosis. Learn why PRTA stock is risky with uncertain upcoming data and past trial disappointments.

Prothena Corporation plc (NASDAQ:PRTA) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ETCompany ParticipantsMark Johnson - Vice President of...

NEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Pro

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please ...

Prothena stock soars despite study miss

U.S. stocks were higher, with the Dow Jones index gaining over 150 points on Thursday. Shares of Accenture plc ACN rose sharply in today's session after the co...

Prothena (PRTA) stock gains even as Parkinson's disease therapy developed with Roche (RHHBY) misses primary endpoint in mid-stage trial. Read more here,

Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease

Prothena Corporation plc's stock has dropped 67% since my last “Buy” rating, primarily due to delays and a lack of meaningful Phase 1 data for PRX012. Read more here.

The rising incidence of Alzheimer's and other tau-related disorders, driven by an aging global population, is significantly boosting the demand for...

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 300 points during on Monday. The Dow traded down 0.71% to 42,012.42...